Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis - PubMed (original) (raw)
Review
. 2010 Jun;95(6):2560-75.
doi: 10.1210/jc.2009-2575.
Mohammad Hassan Murad, Melanie Lane, Juliana F Lampropulos, Felipe Albuquerque, Rebecca J Mullan, Neera Agrwal, Mohamed B Elamin, Juan F Gallegos-Orozco, Amy T Wang, Patricia J Erwin, Shalender Bhasin, Victor M Montori
Affiliations
- PMID: 20525906
- DOI: 10.1210/jc.2009-2575
Review
Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis
M Mercè Fernández-Balsells et al. J Clin Endocrinol Metab. 2010 Jun.
Abstract
Context: The risks of testosterone therapy in men remain poorly understood.
Objective: The aim of this study was to conduct a systematic review and meta-analyses of testosterone trials to evaluate the adverse effects of testosterone treatment in men.
Data sources: We searched MEDLINE, EMBASE, and Cochrane CENTRAL from 2003 through August 2008. Review of reference lists and contact with experts further identified candidate studies.
Study selection: Eligible studies were comparative, randomized, and nonrandomized and reported the effects of testosterone on outcomes of interest (death, cardiovascular events and risk factors, prostate outcomes, and erythrocytosis). Reviewers, working independently and in duplicate, determined study eligibility.
Data extraction: Reviewers working independently and in duplicate determined the methodological quality of studies and collected descriptive, quality, and outcome data.
Data synthesis: The methodological quality of the 51 included studies varied from low to medium, and follow-up duration ranged from 3 months to 3 yr. Testosterone treatment was associated with a significant increase in hemoglobin [weighted mean difference (WMD), 0.80 g/dl; 95% confidence interval (CI), 0.45 to 1.14] and hematocrit (WMD, 3.18%; 95% CI, 1.35 to 5.01), and a decrease in high-density lipoprotein cholesterol (WMD, -0.49 mg/dl; 95% CI, -0.85 to -0.13). There was no significant effect on mortality, prostate, or cardiovascular outcomes.
Conclusions: The adverse effects of testosterone therapy include an increase in hemoglobin and hematocrit and a small decrease in high-density lipoprotein cholesterol. These findings are of unknown clinical significance. Current evidence about the safety of testosterone treatment in men in terms of patient-important outcomes is of low quality and is hampered by the brief study follow-up.
Similar articles
- Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials.
Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Boloña ER, Sideras K, Uraga MV, Erwin PJ, Montori VM. Haddad RM, et al. Mayo Clin Proc. 2007 Jan;82(1):29-39. doi: 10.4065/82.1.29. Mayo Clin Proc. 2007. PMID: 17285783 Review. - Behavioral Counseling to Promote a Healthful Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Known Cardiovascular Disease Risk Factors: Updated Systematic Review for the U.S. Preventive Services Task Force [Internet].
Patnode CD, Evans CV, Senger CA, Redmond N, Lin JS. Patnode CD, et al. Rockville (MD): Agency for Healthcare Research and Quality (US); 2017 Jul. Report No.: 15-05222-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2017 Jul. Report No.: 15-05222-EF-1. PMID: 29364620 Free Books & Documents. Review. - Clinical review: Insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials.
Cosma M, Swiglo BA, Flynn DN, Kurtz DM, Labella ML, Mullan RJ, Elamin MB, Erwin PJ, Montori VM. Cosma M, et al. J Clin Endocrinol Metab. 2008 Apr;93(4):1135-42. doi: 10.1210/jc.2007-2429. Epub 2008 Feb 5. J Clin Endocrinol Metab. 2008. PMID: 18252787 Review. - Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: An Updated Systematic Review for the U.S. Preventive Services Task Force [Internet].
LeBlanc EL, Patnode CD, Webber EM, Redmond N, Rushkin M, O’Connor EA. LeBlanc EL, et al. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Sep. Report No.: 18-05239-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Sep. Report No.: 18-05239-EF-1. PMID: 30354042 Free Books & Documents. Review. - Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials.
Tracz MJ, Sideras K, Boloña ER, Haddad RM, Kennedy CC, Uraga MV, Caples SM, Erwin PJ, Montori VM. Tracz MJ, et al. J Clin Endocrinol Metab. 2006 Jun;91(6):2011-6. doi: 10.1210/jc.2006-0036. Epub 2006 May 23. J Clin Endocrinol Metab. 2006. PMID: 16720668 Review.
Cited by
- Influence of androgens on circulating adiponectin in male and female rodents.
Yarrow JF, Beggs LA, Conover CF, McCoy SC, Beck DT, Borst SE. Yarrow JF, et al. PLoS One. 2012;7(10):e47315. doi: 10.1371/journal.pone.0047315. Epub 2012 Oct 10. PLoS One. 2012. PMID: 23071783 Free PMC article. - Effects of long-term androgen replacement therapy on the physical and mental statuses of aging males with late-onset hypogonadism: a multicenter randomized controlled trial in Japan (EARTH Study).
Konaka H, Sugimoto K, Orikasa H, Iwamoto T, Takamura T, Takeda Y, Shigehara K, Iijima M, Koh E, Namiki M; EARTH study group. Konaka H, et al. Asian J Androl. 2016 Jan-Feb;18(1):25-34. doi: 10.4103/1008-682X.148720. Asian J Androl. 2016. PMID: 25761833 Free PMC article. Clinical Trial. - Male hormonal contraception.
Roth MY. Roth MY. Virtual Mentor. 2012 Feb 1;14(2):126-32. doi: 10.1001/virtualmentor.2012.14.2.stas1-1202. Virtual Mentor. 2012. PMID: 23116954 Free PMC article. Review. No abstract available. - Testosterone, HIV, and cardiovascular disease risk.
Grant JK, Loyd Q, Martinez C. Grant JK, et al. Cardiovasc Endocrinol Metab. 2020 Oct 9;10(2):72-79. doi: 10.1097/XCE.0000000000000236. eCollection 2021 Jun. Cardiovasc Endocrinol Metab. 2020. PMID: 34124602 Free PMC article. Review. - Clomiphene Citrate Treatment as an Alternative Therapeutic Approach for Male Hypogonadism: Mechanisms and Clinical Implications.
Wu YC, Sung WW. Wu YC, et al. Pharmaceuticals (Basel). 2024 Sep 18;17(9):1233. doi: 10.3390/ph17091233. Pharmaceuticals (Basel). 2024. PMID: 39338395 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources